Biotech Firm Nektar Therapeutics Explores Partnership Options

Feb.02 -- Nektar Therapeutics is exploring options including a potential sale of the $15 billion biotechnology firm, according to people with knowledge of the matter. Bloomberg's Ed Hammond reports on "Bloomberg Markets."

(Source: Bloomberg TV - Markets and Finance, February 2, 2018 at 04:22PM)

Recommended posts powered by Google